Adimmune Corporation

NT$16.35As of Sun 8 Nov 2026, 12:00 UTC
TWSE:4142Healthcare
Country Taiwan
PE (Fwd) •••
TSR 10Y CAGR (3.13%)
Div yield —
ROE (4.40%)
Biotechnology
Beta (5Y) 0.29
PE TTM —
TSR TTM (13.95%)
Mkt cap NT$6.892B
ROIC (4.48%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$20
19.73%
(68.77%)
Hold 6|11|1|6|5
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
0.19
0.21
0.23
0.22
(4.23%)
8.95%
17.34%
15.64%
RevenueNT$M
335.9
340.3
344.6
341.7
3.75%
8.19%
8.20%
6.34%
Peers (US$208.1M)
Cap (US$)
PE
210.5M
—
Capital
TTM
5Y
10Y
Leveragex
0.231
0.247
0.259
EBIT/Intx
1.733
0.084
0.084
Own earn%
(59.65)
(93.71)
(73.39)
Sh yield%
14.62
42.41
41.88
Owners
Insiders/Inst%
5.80
47.49
Short interest%
2.17
SBC / revenue%
5.53
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
8–14
$1 testx
—
Incr. ROIC%
14